Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
OncoSil Medical Ltd ( (AU:OSL) ) just unveiled an update.
OncoSil Medical Limited announced that its CEO, Nigel Lange, will present at the 2025 Bell Potter Healthcare Conference in Sydney, Australia. This presentation underscores OncoSil’s commitment to advancing its position in the medical device sector, particularly in the treatment of pancreatic cancer, and highlights the company’s ongoing efforts to expand its market presence and stakeholder engagement.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Limited is a global medical device company specializing in Interventional Oncology. The company focuses on improving cancer treatment outcomes through the intratumoural placement of Phosphorous-32 Microparticles, particularly for unresectable locally advanced pancreatic cancer. OncoSil’s device allows for targeted radiation delivery, sparing surrounding organs, and has received CE Marking approval, enabling its use in over 30 countries, including the EU, UK, Turkey, and Israel.
Average Trading Volume: 23,209
Technical Sentiment Signal: Sell
Current Market Cap: A$21.46M
See more data about OSL stock on TipRanks’ Stock Analysis page.